In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Effects of oxygen administration during CMR imaging in patients with multi-vessel coronary artery disease

Session Poster session 1

Speaker Dominik Guensch

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Systolic and Diastolic Function
  • Session type : Poster Session
  • FP Number : P150

Authors : DP Guensch (Bern,CH), K Fischer (Bern,CH), K Yamaji (Bern,CH), Y Ueki (Bern,CH), B Jung (Bern,CH), L Raber (Bern,CH), H Von Kobligk-Tengg (Bern,CH), B Eberle (Bern,CH)

DP Guensch1 , K Fischer1 , K Yamaji2 , Y Ueki2 , B Jung3 , L Raber2 , H Von Kobligk-Tengg3 , B Eberle1 , 1Bern University Hospital, Department of Anaesthesiology and Pain Medicine - Bern - Switzerland , 2Bern University Hospital, Department of Cardiology - Bern - Switzerland , 3Bern University Hospital, Institute for Diagnostic, Interventional and Paediatric Radiology - Bern - Switzerland ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii99


Hyperoxia is a known coronary vasoconstrictor and it has been shown that supraphysiologic oxygen concentrations reduce coronary blood flow. In patients with coronary artery disease (CAD) this may even induce ischemia. The purpose of this study was to assess the impact of oxygen inhalation on myocardial oxygenation, contractility and relaxation during a cardiovascular magnetic resonance (CMR) scan in patients with multi-vessel CAD.


Twenty-six patients with stable multi-vessel CAD underwent a CMR scan in the interval between staged coronary revascularization procedures. The diameter stenosis (%DS) was assessed by quantitative coronary angiography (QCA). Ten healthy controls underwent the same CMR scan. This included standard cine function imaging and oxygenation-sensitive (OS-)CMR images acquired prior to and after inhaling O2for 5min (10L/min, reservoir mask). Myocardial oxygenation changes were assessed by calculating the %change in OS signal intensity (SI) in end-systolic frames. Global cardiac function and regional contractility using feature tracking strain were analyzed after tracing myocardial contours in systole and diastole.


The mean degree of coronary stenosis was 63±15%. 42% of patients experienced a decrease in OS-SI (-4.5±2.2%), while 29% improved oxygenation (3.2±2.0%). Myocardium perfused via higher-grade stenoses showed more pronounced decreases in tissue oxygenation (r=-0.405, p=0.049). In stenosed segments, the time to peak systolic strain increased 25±39ms during hyperoxia in comparison to normoxia (p=0.005). This was not seen in remote myocardium (p=0.831) or healthy subjects (p=0.857). Depression of diastolic strain rate was associated with more pronounced deterioration of myocardial oxygenation in affected segments (r=0.438, p=0.037) as opposed to normal myocardium (remote: r=0.163, p=0.435; controls: r=-0.077, p=0.856).A decrease in ejection fraction (-6±4 vs. +3±3%) and cardiac index (-0.4±0.2 vs. 0.3±0.3 L/min/m2) was observed in 48% and 64% of patients during hyperoxia, respectively, but not in controls.

Conclusion: In a substantial proportion of patients with CAD, hyperoxia impairs systolic and also diastolic function. The latter is known to be affected early in the ischemic cascade. A higher degree stenosis is associated with more pronounced deoxygenation during hyperoxia. Thus oxygen supplementation may confound systolic and diastolic function assessment in CAD. This may also be true for perfusion studies. In patients with known or suspected CAD, oxygen should only be used during CMR exams to ensure normoxemia, while hyperoxia should be avoided. Further research is warranted to better understand the heterogeneity of the response to oxygen.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are